Patents by Inventor Dieter Roethlisberger

Dieter Roethlisberger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • In Vitro Assays as Indicator of Local Tolerance
    Publication number: 20220137028
    Abstract: The present disclosure is directed to in vitro methods for determining local tolerance. In some embodiments, the in vitro method is a miscibility test.
    Type: Application
    Filed: February 2, 2020
    Publication date: May 5, 2022
    Inventors: Peter Bruegger, Dieter Roethlisberger, Hanns-Christian Mahler
  • Galenic composition for low bioavailability medicaments
    Patent number: 6719996
    Abstract: A pharmaceutical composition for oral administration of an active compound having a bioavailability of 20% or less. The composition comprises, based on its total weight, from 0.01% to about 15% (w/w) of said active compound molecularly dissolved in the composition, from 30 to 80% (w/w) of an edible lipid matrix and from 1 to 20% (w/w) of an edible emulsifier, the ratio between the dose weight of the active compound and its solubility in the composition being equal to or greater than 0.6 ml. The high percentage of fat (30-80%) enables a considerable increase the amount of the drug that is molecularly dispersed in the dosage form, thus allowing a significant reduction in the number of unit doses that must be taken daily-by patients.
    Type: Grant
    Filed: December 10, 2001
    Date of Patent: April 13, 2004
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Martin Kuentz, Dieter Roethlisberger
  • Galenic composition for low bioavailability medicaments
    Publication number: 20020114837
    Abstract: A pharmaceutical composition for oral administration of an active compound having a bioavailability of 20% or less. The composition comprises, based on its total weight, from 0.01% to about 15% (w/w) of said active compound molecularly dissolved in the composition, from 30 to 80% (w/w) of an edible lipid matrix and from 1 to 20% (w/w) of an edible emulsifier, the ratio between the dose weight of the active compound and its solubility in the composition being equal to or greater than 0.6 ml. The high percentage of fat (30-80%) enables a considerable increase the amount of the drug that is molecularly dispersed in the dosage form, thus allowing a significant reduction in the number of unit doses that must be taken daily-by patients.
    Type: Application
    Filed: December 10, 2001
    Publication date: August 22, 2002
    Inventors: Martin Kuentz, Dieter Roethlisberger